Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Easywell BiomedicalsROCO:1799 -5.43%55 Days Payable is 17.85 as of Dec. 2025, which is 32% below its 10-year median of 26.15. GuruFocus rates ROCO:1799 with a GF Score™ of 55/100 and a GF Value™ of NT$75.37 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Easywell Biomedicals ranks worse than 95.15% on this metric.
The historical rank and industry rank for Easywell Biomedicals's Days Payable or its related term are showing as below:
ROCO:1799'
s Days Payable Range Over the Past 10 Years
Min: 1.07 Med: 26.15 Max: 57.76
Current: 20.68
During the past 13 years, Easywell Biomedicals's highest Days Payable was 57.76. The lowest was 1.07. And the median was 26.15.
ROCO:1799's Days Payable is ranked worse than 95.15% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs ROCO:1799: 20.68
Easywell Biomedicals's Days Payable
declined
from Dec. 2024 (77.34) to Dec. 2025 (17.85).
It may suggest that Easywell Biomedicalsaccelerated paying its suppliers.
Easywell Biomedicals Days Payable Related Terms
Easywell Biomedicals Days Payable Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's Days Payable distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Easywell Biomedicals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easywell Biomedicals (ROCO:1799) has a Days Payable of 17.85 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Easywell Biomedicals and its competitors. This is 32% below median its historical median of 26.15. Over the past decade, Easywell Biomedicals' Days Payable has ranged from 1.07 to 57.76. According to the industry distribution chart, Easywell Biomedicals ranks #882 out of 927 companies in the Drug Manufacturers industry, placing it in the top 95.1%.
Is Easywell Biomedicals' Days Payable too high?
Easywell Biomedicals' current Days Payable of 17.85 is 32% below median its 10-year median of 26.15. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 57.76. The Drug Manufacturers industry median Days Payable is 90.38. Easywell Biomedicals' value of 17.85 is 80.3% below this industry median. Based on the distribution chart, Easywell Biomedicals ranks #882 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #882 out of 927 companies for Days Payable. This places Easywell Biomedicals in the lower half of its industry. The industry median Days Payable is 90.38. Easywell Biomedicals' value of 17.85 is 80.3% below this benchmark. Historically, Easywell Biomedicals' own Days Payable has ranged from 1.07 to 57.76 over the past decade. While the company's 10-year median is 26.15 vs. the industry median of 90.38, Easywell Biomedicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Easywell Biomedicals's current Days Payable of 17.85 is 80.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Easywell Biomedicals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current Days Payable is 17.85, which is 32% below median its own 10-year median of 26.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.37, compared to a current price of NT$32.25 — trading 57.2% below its estimated fair value. The current Days Payable is 17.85, which is 32% below median its 10-year median of 26.15 and 80.3% below the Drug Manufacturers industry median of 90.38. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Days Payable is 17.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$32.25 is trading 57.2% below its estimated GF Value™ of NT$75.37.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
Days Payable: 17.85 (32% below median its 10-year median of 26.15)
GF Value™: NT$75.37 vs. price of NT$32.25 (57.2% below fair value)
Industry Position: 80.3% below the Drug Manufacturers median (#882 of 927)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score
Get the complete analysis for ROCO:1799
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
